Posterior Uveitis Associated with Cemiplimab.
Sign Up to like & getrecommendations! Published in 2021 at "Ocular immunology and inflammation"
DOI: 10.1080/09273948.2021.1872649
Abstract: PURPOSE The immune checkpoint inhibitors (ICPIs) comprise a class of oncologic immunotherapies. The most recent US Food and Drug Administration-approved ICPI is cemiplimab (Libtayo®). Cemiplimab, like the other ICPIs, blocks checkpoint receptors in order to… read more here.
Keywords: posterior uveitis; treatment; cemiplimab; associated cemiplimab ... See more keywords